P+R-ICE: A phase 2 trial of pembrolizumab with R-ICE chemotherapy in relapsed/refractory diffuse large B-cell lymphoma

This phase 2 trial is testing the combination of pembrolizumab with R-ICE chemotherapy in people with relapsed or refractory diffuse large B-cell (DLBCL).

You can share the following clinicaltrials.gov identifier with your medical team so they can find out about the trial: NCT05221645 

Trial aim and background 

The aim of this trial is to find out the safety and efficacy of using pembrolizumab in combination with rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) in adults with DLBCL that has either come back (relapsed) or not responded to previous treatment (refractory). 

Participants will be randomly allocated to one of two groups. This will either be the control arm which is R-ICE for 3 cycles followed by an autologous stem cell transplant, or the experimental arm which will be R-ICE plus pembrolizumab (P+R-ICE) for 3 cycles followed by an autologous stem cell transplant and maintenance pembrolizumab every 3 weeks for one year.

Who can enter

Adults over 18 with confirmed CD20 +ve DLBCL who have relapsed or not responded to first line or second line treatments with rituximab may be eligible to apply.

Locations

Recruitment is taking place in the following UK locations:

  • Oxford Cancer & Haematology Centre, Oxford
  • The Beatson West of Scotland Cancer Centre, Glasgow

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/ct2/show/NCT05221645 

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.